Answers are grounded in this paper and cite their sources.
Observational findings reveal marked palliative benefits from mifepristone treatment in metastatic breast cancer, suggesting broader therapeutic implications.
Mifepristone provided marked palliative benefit in this patient with nPR-negative, metastatic breast cancer, suggesting potential therapeutic value in similar cases. Confirmation of efficacy will require larger studies focused on tumors with absent or minimal nuclear progesterone receptor expression.
No takes yet. Share an insight, caveat, or question.
CHECK et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: